Trial · NCT06923709
Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease
NCT06923709, Phase 2, Recruiting, Odense University Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease. Trials, record NCT06923709. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06923709
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Beneficial Effect of Amiloride on Progression of Chronic Kidney Disease
- NCT number
- NCT06923709
- Status
- Recruiting
- Phases
- Phase 2
- Enrollment
- 40 participants, estimated
- Lead sponsor
- Odense University Hospital
- Conditions
- Chronic Kidney Disease(CKD), Proteinuria
- Interventions
- amiloride, Placebo
- First posted
- 2025-04-11
- Last updated
- 2025-04-11
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Urine-C3a (ng/ml) | Measured before (day one) and after (day 8) each treatment period | Urine-C3a is measured in spot urine samples and expressed as u-C3a/creatinine (µg/g) to account for the dilution factor. |
| Primary | Urine C5-9-sTCC/MAC (U/ml) | Measured before (day one) and after (day 8) each treatment period | Membrane Attack Complex (MAC) of the complement system, specifically targeting the C5 to C9 proteins. u-C5-9 is measured in spot urine samples and expressed as u-C5-9/creatinine U/µmol to account for the dilution factor. |
| Primary | Kidney Injury Molecule-1 (KIM-1) pg/ml | Measured before (day one) and after (day 8) each treatment period | KIM-1 is a protein that serves as a biomarker used particularly in the context of kidney injury |
| Primary | Neutrophil Gelatinase-Associated Lipocalin (NGAL) (pg/mL) | Measured before and after each treatment period | NGAL is a protein associated with neutrophils used as a biomarker in the context of kidney injury. |
| Secondary | Urine albumin/creatinin ratio (mg/g) | Measured before (day one) and after (day 8) each treatment period | In spot urine samples, albumin and creatinin are measured |
| Secondary | Urine protein/creatinin ratio | Measured before (day one) and after (day 8) each treatment period | In spot urine samples, albumin and creatinin are measured |
| Secondary | Home blood pressure (mmHg) | Measured before (day one) and after (day 8) each treatment period | Home blood pressure are measured according to standard guidelines |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06923709
GET https://conductscience.org/api/trials/v1/NCT06923709/registered